| PU16.14 | Building public-private partnerships for pharmacy-based PrEP delivery in Kenya: willingness to collaborate among PrEP and pharmacy providers | Publication Only | Implementation science, including structural interventions, PrEP & VMMC |
| PU16.15 | Multilevel barriers to PrEP uptake and adherence among Black and Hispanic/Latinx transgender women in Southern California | Publication Only | Implementation science, including structural interventions, PrEP & VMMC |
| PU18.01 | Simple tool for geographic prioritization of PrEP for adolescent girls and young women based on cost-effectiveness | Publication Only | Mathematical modelling: impact and effectiveness |
| PU18.02LB | Modeling the probability of HIV infection and its reduction by microbicides using deterministic mass transport theory coupled to viral dynamics | Publication Only | Mathematical modelling: impact and effectiveness |
| PU19.01 | The impact of vaginal Lactobacillus isolates on host gene expression involved in inflammation in the female genital tract | Publication Only | Microbiome & STI: impact on prevention |
| PU20.01 | Vaccination with Ad26.ZEBOV, MVA-BN-Filo or MVA-BN-Filo, Ad26.ZEBOV induced predominantly IgG binding to Ebola glycoprotein in cervico-vaginal mucus in HIV-infected and uninfected participants | Publication Only | Mucosal immunity |
| PU20.02 | Asymptomatic bacterial STI in young men who have sex with men minimally alters rectal mucosal immune cell ecosystem | Publication Only | Mucosal immunity |
| PU21.01 | Willingness of adolescent girls and young women in Kampala, Uganda to participate in future efficacyttrials of novel biomedical HIV prevention interventions: the anti-retroviral implant | Publication Only | Novel vaccine and other prevention approaches |
| PU21.02 | Comparison of HIV incidence in simulated vaccine efficacy trials and observational cohorts using propensity scores in key populations in Uganda | Publication Only | Novel vaccine and other prevention approaches |
| PU21.03 | Co-display of hyperstabilized HIV-1 envelope glycoprotein trimers on two-component protein nanoparticles | Publication Only | Novel vaccine and other prevention approaches |